Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/CHP1_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/CHP1_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/CHP1_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/CHP1_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/CHP1_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/CHP1_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/CHP1_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003367325 | Thyroid | ATC | negative regulation of kinase activity | 122/6293 | 237/18723 | 9.19e-09 | 1.94e-07 | 122 |
GO:190121428 | Thyroid | ATC | regulation of neuron death | 156/6293 | 319/18723 | 9.30e-09 | 1.96e-07 | 156 |
GO:190353316 | Thyroid | ATC | regulation of protein targeting | 51/6293 | 81/18723 | 6.02e-08 | 1.07e-06 | 51 |
GO:0051650110 | Thyroid | ATC | establishment of vesicle localization | 87/6293 | 161/18723 | 7.16e-08 | 1.25e-06 | 87 |
GO:005117018 | Thyroid | ATC | import into nucleus | 86/6293 | 159/18723 | 8.02e-08 | 1.40e-06 | 86 |
GO:190382816 | Thyroid | ATC | negative regulation of cellular protein localization | 67/6293 | 117/18723 | 1.23e-07 | 2.06e-06 | 67 |
GO:004677717 | Thyroid | ATC | protein autophosphorylation | 114/6293 | 227/18723 | 1.54e-07 | 2.49e-06 | 114 |
GO:000660617 | Thyroid | ATC | protein import into nucleus | 83/6293 | 155/18723 | 2.38e-07 | 3.70e-06 | 83 |
GO:190458918 | Thyroid | ATC | regulation of protein import | 41/6293 | 63/18723 | 3.19e-07 | 4.76e-06 | 41 |
GO:005164818 | Thyroid | ATC | vesicle localization | 91/6293 | 177/18723 | 7.21e-07 | 9.64e-06 | 91 |
GO:0035303113 | Thyroid | ATC | regulation of dephosphorylation | 70/6293 | 128/18723 | 7.24e-07 | 9.65e-06 | 70 |
GO:004230617 | Thyroid | ATC | regulation of protein import into nucleus | 38/6293 | 60/18723 | 2.34e-06 | 2.76e-05 | 38 |
GO:000690315 | Thyroid | ATC | vesicle targeting | 30/6293 | 45/18723 | 5.89e-06 | 6.18e-05 | 30 |
GO:1905477111 | Thyroid | ATC | positive regulation of protein localization to membrane | 58/6293 | 106/18723 | 6.14e-06 | 6.42e-05 | 58 |
GO:002240622 | Thyroid | ATC | membrane docking | 49/6293 | 86/18723 | 7.13e-06 | 7.34e-05 | 49 |
GO:005109022 | Thyroid | ATC | regulation of DNA-binding transcription factor activity | 190/6293 | 440/18723 | 1.49e-05 | 1.39e-04 | 190 |
GO:001092117 | Thyroid | ATC | regulation of phosphatase activity | 47/6293 | 84/18723 | 2.09e-05 | 1.87e-04 | 47 |
GO:004828413 | Thyroid | ATC | organelle fusion | 71/6293 | 141/18723 | 2.83e-05 | 2.38e-04 | 71 |
GO:003112215 | Thyroid | ATC | cytoplasmic microtubule organization | 34/6293 | 56/18723 | 2.92e-05 | 2.45e-04 | 34 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CHP1 | SNV | Missense_Mutation | rs79101281 | c.466N>A | p.Ala156Thr | p.A156T | Q99653 | protein_coding | tolerated(0.18) | benign(0.025) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
CHP1 | deletion | Frame_Shift_Del | novel | c.298delN | p.Asp101MetfsTer2 | p.D101Mfs*2 | Q99653 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
CHP1 | SNV | Missense_Mutation | | c.73N>T | p.His25Tyr | p.H25Y | Q99653 | protein_coding | deleterious(0.04) | benign(0.068) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
CHP1 | SNV | Missense_Mutation | novel | c.280N>A | p.Glu94Lys | p.E94K | Q99653 | protein_coding | tolerated(0.58) | benign(0.001) | TCGA-ZJ-AAXT-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
CHP1 | SNV | Missense_Mutation | rs767999244 | c.254G>A | p.Arg85Gln | p.R85Q | Q99653 | protein_coding | tolerated(0.09) | benign(0.154) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
CHP1 | SNV | Missense_Mutation | rs770704424 | c.419G>A | p.Arg140His | p.R140H | Q99653 | protein_coding | tolerated(0.32) | benign(0.006) | TCGA-EI-6917-01 | Colorectum | rectum adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5fluorouracil+oxaciplatina+l-folinian | SD |
CHP1 | SNV | Missense_Mutation | novel | c.580N>A | p.Leu194Ile | p.L194I | Q99653 | protein_coding | deleterious(0.02) | probably_damaging(0.966) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
CHP1 | SNV | Missense_Mutation | | c.329G>A | p.Ser110Asn | p.S110N | Q99653 | protein_coding | tolerated(0.09) | benign(0.007) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CHP1 | SNV | Missense_Mutation | novel | c.580N>A | p.Leu194Ile | p.L194I | Q99653 | protein_coding | deleterious(0.02) | probably_damaging(0.966) | TCGA-B5-A1MR-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
CHP1 | SNV | Missense_Mutation | | c.292N>G | p.Lys98Glu | p.K98E | Q99653 | protein_coding | tolerated(0.35) | benign(0) | TCGA-BS-A0UJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |